



Current Funding Opportunities — March 2018

**1) U.S. Tobacco Control Policies to Reduce Health Disparities (R21 Clinical Trial Optional)**  
**([PAR-18-674](#))**

**SPONSOR: National Cancer Institute**

**Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing cancer health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies. Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use cancer health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce cancer health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups.

Application Receipt Dates: Multiple dates, see announcement

**2) Basic Research in Cancer Health Disparities (R01 Clinical Trials Not Allowed)**  
**([PAR-18-654](#))**

**SPONSOR: National Cancer Institute**

**Synopsis:** This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses.

Application Receipt/Submission Date(s): Multiple dates, see announcement

**3) Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R01 Clinical Trial Optional)**  
**([PAR-18-605](#))**

**SPONSOR: National Cancer Institute**

**Synopsis:** This Funding Opportunity Announcement (FOA) encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as chemobrain. A better understanding of the acute- and late-term cognitive changes following exposure to adjuvant chemotherapy and molecularly-targeted treatments, including hormonal therapy, for non-central nervous system tumors can inform clinical assessment protocols with downstream implications for survivorship care plans.

Application Receipt Dates: Multiple dates, see announcement